Your Health, We Care
Since obtaining approval from the US Food and Drug Administration (FDA) in 2006, Sunitinib has been widely used in clinical practice.
Sunitinib can inhibit the proliferation and spread of tumor cells by suppressing the activity of tyrosine kinase receptors such as KIT, PDGFR α, and VEGFR, thereby exerting anti-tumor effects.
